Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) recently reported positive Phase 1 data for a leading drug candidate. The study saw the drug tested in 45 patients and the outcome strengthened the confidence of Cyclacel insider that the compound has a bright future.
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is one of the companies engaged in the development of cancer treatments. The compound whose Phase 1 trial results were recently shared targeted patients afflicted by various cancers including breast, pancreatic and ovarian cancers. Cyclacel’s compound aimed at these cancers is a combination of two of the company’s drugs namely seliciclib and sapacitabine.
Strong positive response to Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)
The patients who received treatment of Cyclacel’s compound demonstrated significant improvements in the conditions. Not only did the compound improve the disease condition of the trial patients, but it also showed strong safety profile.
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)’s combination treatment is an orally administered drug. The study tested the drug in two segments known as Part 1 and Part 2. Based on the positive results of the Part 1 and 2 studies, CYCC will be taking the development of the compound to the next level in a Part 3 study. As such, the company revealed it was already in the process of enrolling patients with breast cancer for the third segment of the study.
According to Cyclacel’s VP of clinical development, Judy Chiao, if the Part 3 study confirms the findings of Part 1 and Part 2 findings, they would be almost certain that they have a potentially transformative drug in the making.
According to Cyclacel’s CEO, Spiro Rombotis, the other exciting thing about the lead compound they are developing is the durability of responses. Treatment duration was noted to exceed 4.5 years. As such, the Part 3 study should help with better understanding of the compound and its potential benefits.
If Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) hits a success with the compound, it would provide relief for many patients afflicted by breast cancer and other forms of cancer. The company also hopes to unlock a lucrative revenue stream.